Aspirin use and ovarian cancer risk using extended follow-up of the PLCO Cancer Screening Trial.

ABSTRACT:

Objective

Frequent use of aspirin has been associated with reduced ovarian cancer risk in observational studies, but it is unclear if only daily, low-dose aspirin confers a protective benefit. We examined associations between patterns of aspirin use and ovarian cancer risk among postmenopausal women in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Methods

Participants were enrolled in PLCO between 1993 and 2001 and followed for cancer outcomes through 2014. Detailed data on aspirin use (e.g., dose, frequency and duration) were ascertained via the supplemental questionnaire (SQX) administered in 2006-2007. We used Cox proportional hazards regression to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between aspiri

SUBMITTER: Hurwitz LM 

PROVIDER: S-EPMC7584756 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature